0 144

Cited 0 times in

Durvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study

DC Field Value Language
dc.date.accessioned2023-06-02T00:49:51Z-
dc.date.available2023-06-02T00:49:51Z-
dc.date.issued2022-05-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194456-
dc.description.statementOfResponsibilityrestriction-
dc.relation.isPartOfPNEUMOLOGIE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleDurvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorN Reinmuth-
dc.contributor.googleauthorM L Johnson-
dc.contributor.googleauthorB C Cho-
dc.contributor.googleauthorA Luft-
dc.contributor.googleauthorJ A Alatorre-Alexander-
dc.contributor.googleauthorS L Geater-
dc.contributor.googleauthorK Laktionov-
dc.contributor.googleauthorA Vasilyev-
dc.contributor.googleauthorD Trukhin-
dc.contributor.googleauthorS W Kim-
dc.contributor.googleauthorG Ursol-
dc.contributor.googleauthorM Hussein-
dc.contributor.googleauthorF L Lim-
dc.contributor.googleauthorC T Yang-
dc.contributor.googleauthorL H Araujo-
dc.contributor.googleauthorH Saito-
dc.contributor.googleauthorX Shi-
dc.contributor.googleauthorL Poole-
dc.contributor.googleauthorS Peters-
dc.contributor.googleauthorE B Garon-
dc.contributor.googleauthorT Mok-
dc.contributor.googleauthorJ Rawluk-
dc.identifier.doi10.1055/s-0042-1747796-
dc.relation.journalcodeJ04444-
dc.identifier.urlhttps://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-1747796-
dc.citation.volume76-
dc.citation.numberSuppl 1-
dc.citation.startPageS48-
dc.identifier.bibliographicCitationPNEUMOLOGIE, Vol.76(Suppl 1) : S48, 2022-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.